» Articles » PMID: 3528541

Disulfiram Treatment of Alcoholism. A Veterans Administration Cooperative Study

Overview
Journal JAMA
Specialty General Medicine
Date 1986 Sep 19
PMID 3528541
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

We conducted a controlled, blinded, multicenter study of disulfiram treatment of alcoholism in 605 men randomly assigned to 250 mg of disulfiram (202 men); 1 mg of disulfiram (204 men), a control for the threat of the disulfiram-ethanol reaction; or no disulfiram (199 men), a control for the counseling that all received. Bimonthly treatment assessments were done for one year. Relative/friend interviews and blood and urine ethanol analyses were used to corroborate patients' reports. There were no significant differences among the groups in total abstinence, time to first drink, employment, or social stability. Among the patients who drank and had a complete set of assessment interviews, those in the 250-mg disulfiram group reported significantly fewer drinking days (49.0 +/- 8.4) than those in the 1-mg (75.4 +/- 11.9) or the no-disulfiram (86.5 +/- 13.6) groups. There was a significant relationship between adherence to drug regimen and complete abstinence in all groups. We conclude that disulfiram may help reduce drinking frequency after relapse, but does not enhance counseling in aiding alcoholic patients to sustain continuous abstinence or delay the resumption of drinking.

Citing Articles

Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies.

Huang D, Yao Y, Lou Y, Kou L, Yao Q, Chen R Int J Pharm X. 2024; 8:100307.

PMID: 39678262 PMC: 11638648. DOI: 10.1016/j.ijpx.2024.100307.


Remission from addiction: erasing the wrong circuits or making new ones?.

Engeln M, Ahmed S Nat Rev Neurosci. 2024; 26(2):115-130.

PMID: 39663409 DOI: 10.1038/s41583-024-00886-y.


Video Record Viewing of Self in Delirium Tremens (VVSDT) and its Effect on Abstinence among Patients with Alcohol Dependence Syndrome.

Patil S, Mattikoppa N, Gowda M Indian J Psychol Med. 2024; :02537176241260468.

PMID: 39564221 PMC: 11572504. DOI: 10.1177/02537176241260468.


Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder.

Belnap M, McManus K, Grodin E, Ray L Pharmaceut Med. 2024; 38(4):291-302.

PMID: 38967906 PMC: 11272707. DOI: 10.1007/s40290-024-00526-x.


Repurposing disulfiram with CuET nanocrystals: Enhancing anti-pyroptotic effect through NLRP3 inflammasome inhibition for treating inflammatory bowel diseases.

Xu X, Han Y, Deng J, Wang S, Zhuo S, Zhao K Acta Pharm Sin B. 2024; 14(6):2698-2715.

PMID: 38828135 PMC: 11143773. DOI: 10.1016/j.apsb.2024.03.003.